CMYA5 (cardiomyopathy associated 5) is a multifunctional protein with primary roles in cardiac and skeletal muscle organization. In striated muscle, CMYA5 acts as a master scaffolding protein essential for assembling cardiac dyads and ryanodine receptor (RYR2) clusters 1, nanoscale structures critical for excitation-contraction coupling 2. CMYA5 interacts with multiple binding partners including Speg, Esd, Fsd2, and desmin to stabilize these complexes 13. Beyond muscle, CMYA5 likely functions as a PKA-anchoring protein and calcineurin repressor, potentially modulating skeletal muscle regeneration. Genetically, CMYA5 variants show significant psychiatric associations. Multiple SNPs (rs10043986, rs4704591) associate with schizophrenia risk across populations 4, though an updated meta-analysis questions this in Asian populations 5. CMYA5 polymorphisms also confer risk for major depressive disorder in Han Chinese populations 6. The schizophrenia-associated rs10043986 variant (Pro→Leu) demonstrates altered binding affinity to desmin, potentially affecting cytoskeletal organization in neuronal cells 3. Clinically, CMYA5 emerges as a therapeutic target: virally-delivered miniaturized CMYA5 restores dyad architecture and cardiac function under stress 2, suggesting potential for treating heart failure. The gene's broad tissue expression and protein interaction networks indicate roles beyond those currently characterized.